Key facts
- This page summarizes Charles Theuer's Form 4 filing for Tracon Pharmaceuticals, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Mar 2024, 17:56.
Charles Theuer - 12 Mar 2024 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.
- Reporting relationship
- PRESIDENT AND CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 12 Mar 2024
- Net transaction value
- +$948
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2024, 17:56:13 UTC
- Prior SEC filing
- 30 Jun 2023
- Next SEC filing
- 23 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott B. Brown, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Charles Theuer filed Form 4 for Tracon Pharmaceuticals, Inc. on 13 Mar 2024.
Change
- Previous filing in this sequence was filed on 30 Jun 2023.
- Current net transaction value: +$948.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCON
transaction
Common Stock
Award
- Transaction value
- $482
- Shares
- +3,500
- Change %
- +0.88%
- Price
- $0.1377
- Shares after
- 402,917
- Date
- 20 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
TCON
transaction
Common Stock
Award
- Transaction value
- $467
- Shares
- +3,500
- Change %
- +0.87%
- Price
- $0.1333
- Shares after
- 406,417
- Date
- 20 Oct 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TCON
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +518,300
- Change %
- Price
- $0.000000
- Shares after
- 518,300
- Date
- 12 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 518,300
- Exercise price
- $0.3900
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.
Footnote F2
Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2023.
Footnote F3
1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month.